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Epidemiology of esophageal cancer
Esophageal cancer (EC) is the eighth common cancer worldwide 
causing over 400,000 deaths in 2008.1 It is responsible for about 
5.4% of all cancer-related deaths and was reported as the sixth 
most common cause of death from cancer.1 Considerable varia-
tions were reported for incidence of EC between different parts 
of the world. A geographic area extending from northern Iran to 
north-central China (Asian belt of EC) was considered as high- risk 
area for EC.2–4 Areas with intermediate risk of EC include South-
east Africa and parts of South America.3 Other parts of the world 
including the USA were reported as low-risk ones.1 EC is more 
common in men and more than 80% of cases occur in developing 
countries.1 Squamous cell carcinoma (SCC) and adenocarcinoma 
are the most common types of EC.2,5 Reports in the 1960s sug-
gested that the morphologic diagnosis in about 90% of EC cases 
were esophageal SCC (ESCC).3 Although recent studies showed 
an increase in esophageal adenocarcinoma and a decrease in ESCC 
in the Western countries,6–8 other reports from developing world 
including Iran suggested that ESCC still comprises more than 90% 
of EC cases.9,10 So, ESCC remains the most common type of EC 
in the developing world and an important health problem in high- 
risk areas.11
 Pathogenesis and etiology of ESCC
ESCC typically occurs by progression from dysplastic lesions 
within the normal squamous epithelium of the esophagus (Figure 
1).3 Esophageal squamous dysplasia (ESD) has been suggested 
as the only clinically important premalignant precursor lesion for 
ESCC.12,13(6'VDUHFODVVL¿HGLQWRWZRJURXSV7KH¿UVWLVORZ
grade dysplasia, which includes mild and moderate dysplasia. The 
second is high-grade dysplasia, which includes severe dysplasia.3 
Over months to years ESDs grow into tumor mass (ESCC).14  
Various factors may increase the risk of ESCC.15 These factors 
affect on the process of ESD development and its progression 
into ESCC. Genetic susceptibility was suggested to play a role in 
pathogenesis of ESCC.16,17 Relationships between some environ-
mental factors and the risk of ESCC were reported.18,19 Patients’ 
characteristics including alcohol drinking,20 tobacco smoking,20,21 
opium consumption,21 nass chewing,21 hot tea consumption,22 mate 
drinking,23 low intake of fruits and vegetables,24 low socioeconom-
ic status,25 and tooth loss26 may play role in development of ESCC. 
So, ESCC is a complex and multifactorial disease.
Prognosis of ESCC
Esophageal wall does not have true serosal layer. This makes 
ESCC a progressive cancer with relatively rapid invasion into 
neighboring structures.27 Most of ESCC cases present in late stag-
es, resulting in delayed diagnosis of the disease. Consequently, 
SURJQRVLVLVSRRULQWKHVHSDWLHQWV7KHRYHUDOO¿YH\HDUVXUYLYDO
of ESCC patients was reported as low as 9%.14 But, if the disease 
is detected in early stages, the survival rates will be considerably 
improved. Results of a study on 230 EC cases suggested that the 
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(QGRVFRSLF6FUHHQLQJIRU(6&&
¿YH\HDUVXUYLYDOUDWHLQSDWLHQWVZLWKPXFRVDOFDQFHUZDV
higher than those with submucosal cancer (64%).28 Wang, et al. 
UHSRUWHG¿YH\HDUVXUYLYDOUDWHVRIDQGLQHDUO\VWDJHV
of EC cases with esophagectomy and endoscopic mucosectomy, 
respectively.29,QDQRWKHUVWXG\IURP-DSDQWKH¿YH\HDUVXUYLYDO
rates in EC with stages 0, I, and IIA-IVB were 83%, 47%, and 
0%, respectively.30 Generally, the survival rate of EC was higher 
in high-income countries31,32 than low- and middle- income coun-
tries.33,34 
Detecting ESCC in earlier stages will decrease the costs, inci-
dence, mortality, and consequently the burden of the disease.35 Liu, 
et al. and Yang J, et al. showed that detecting and treating EC pa-
tients in early stages will result in a considerable reduction in costs 
DQGLQFUHDVHLQEHQH¿WV36,37 Regarding the results of a study from 
Italy, lymph node metastasis did not occur in patients with lesions 
restricted to esophageal mucosa including ESDs and intraepithelial 
neoplasia (carcinoma in situ).38 After invasion to submucosa, the 
rate of lymph node metastasis will increase dramatically. So, it is 
important to detect and control the disease in earlier stages. Detec-
tion and treatment of mucosal lesions will result in the best progno-
sis. Detecting these lesions should be considered as the main aim 
in early ESCC detection programs.
     
Controlling programs for ESCC
Appropriate treatment modality is usually selected for ESCC pa-
tients according to the stage of tumor.3 Mucosal lesions including 
ESDs and carcinoma in situ are treated by endoscopic mucosal 
resection (EMR), while the therapeutic options in localized ESCC 
include surgical resection, radiotherapy, and chemotherapy.3 Pa-
tients with advanced stage of ESCC may be treated by endoscopic 
palliative therapies such as laser therapy, argon plasma coagula-
tion, esophageal dilation, and esophageal stent replacement.3 De-
spite availability of a wide range of therapeutic options, preven-
tion is the most effective strategy to control ESCC. Primary and 
secondary preventive methods may be considered for ESCC. In 
primary prevention, we try to prevent the initiation of the ESD 
(Figure 1). But ESD is a multifactorial condition and it may not 
be possible to identify and eliminate all of its risk factors. The aim 
of secondary prevention is to detect and eliminate ESD, prevent-
ing its progression into advanced stages. As mentioned earlier, the 
therapeutic options and prognosis of mucosal ESCC (carcinoma in 
situ) is the same as high-grade ESD. Therefore, carcinoma in situ 
of the esophagus may also be considered as an appropriate target 
in secondary prevention of ESCC. Endoscopic therapeutic options 
including EMR result in complete elimination of these mucosal 
lesions and give a normal life with high quality to the patients.39 
   
Screening methods for ESCC
$VFUHHQLQJPHWKRGPLJKWKDYHSRWHQWLDOEHQH¿WIRUDGLVHDVHLI
the following assumptions are true about it. Firstly, the disease in 
all or most of cases starts from a detectable preclinical phase. Sec-
ondly, in the absence of intervention, most or all cases in preclini-
cal phase progress into clinical one.40 In case of ESCC, both of the 
above- mentioned assumptions are true.14 So, screening programs 
FDQEHHI¿FLHQWDQGKHOSIXOIRUFRQWUROOLQJ(6&&6HFRQGDU\SUH-
vention (to detect ESD and carcinoma in situ) has been consid-
ered as basic design in screening programs of ESCC. Endoscopy 
is the diagnostic choice for esophageal mucosal lesions.3,41 But it is 
an invasive and expensive method and especially is not accepted 
by asymptomatic cases.427KHUHIRUH LQYHVWLJDWRUV WULHG WR¿QGD
nonendoscopic screening method by considering a combination 
of various modalities such as cytologic examination and existence 
of various risk factors and molecular markers.43 Despite the large 
number of studies conducted throughout the world, no method has 
\HWEHHQDSSURYHGDVDQHI¿FLHQWQRQHQGRVFRSLF(6&&VFUHHQLQJ
test,3,44 and endoscopy remains as the best option for ESCC screen-
ing programs. A large number of studies have been conducted to 
develop the best endoscopic method for ESCC screening. We will 
Figure 1. Pathogenesis, etiology, and controlling methods of esophageal squamous cell 
carcinoma (ESCC).
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discuss about the details and results of these studies in the follow-
ing section of this paper.
Endoscopy with iodine staining
7KH¿UVWDQGPRVWLPSRUWDQWVWHSRI(6&&VFUHHQLQJSURJUDPVLV
to detect its premalignant lesions (ESD) as well as early-stage ma-
lignant lesions (carcinoma in situ). Endoscopy is considered as the 
method of choice for detecting these lesions and taking biopsy for 
KLVWRORJLFFRQ¿UPDWLRQ+RZHYHUWKHVHOHVLRQVDUHJHQHUDOO\LQ-
visible during conventional white-light endoscopic examination of 
HVRSKDJHDOOXPHQ6RLQYHVWLJDWRUVWULHGWR¿QGDPHWKRGWRPDNH
mucosal lesions visible through endoscopic examination. Schiller 
IRU WKH¿UVW WLPH LQWURGXFHGDPHWKRG WRKLJKOLJKWSUHPDOLJQDQW
lesions (squamous dysplasia) of the cervix. They considered io-
dine staining for early detection of mucosal abnormalities of the 
cervix.45 As epithelial cells of the cervix and esophagus are both of 
squamous cell type, a similar staining technique has been applied 
since the late 1960s to detect mucosal lesions of the esophagus.46–49
7KH VXSHU¿FLDO HSLWKHOLXP RI WKH QRUPDO VTXDPRXV HSLWKHOLD
(e.g., in the esophagus and cervix) contains abundant glycogen. 
Basically, iodine stains glycogen brown.50,51 So, if normal esopha-
geal epithelium is exposed to iodine, its color changes into dark 
brown. The glycogen content in abnormal mucosal lesion includ-
ing squamous dysplasia and carcinoma in situ is very low, and the 
areas with those lesions remain unstained, so called as unstained 
lesion in endoscopic examination.52,53 
Endoscopy with iodine (Lugol’s solution) staining of the esopha-
geal mucosa, so called as chromoendoscopy, has been used to de-
tect esophageal mucosal lesions and suggested to be considered in 
ESCC early detection (screening) programs in different popula-
tions. Mandard, et al. used iodine staining in 37 esophageal speci-
mens. They found normal esophageal mucosa as iodine-positive 
and invasive carcinoma and dysplastic lesions as iodine-negative 
]RQHV7KH\¿QDOO\VXJJHVWHGLRGLQHVWDLQLQJIRUHDUO\HQGRVFRSLF
diagnosis of EC.54 The usefulness of iodine staining to improve 
early detection of esophageal squamous neoplasia was reported by 
some investigators.55–63 
These studies were conducted on different high- risk populations. 
The results of a study from Brazil on patients with head and neck 
cancer, showed that Lugol chromoendoscopy diagnosed 100% 
of high-grade intraepithelial neoplasia while the detection rate 
by standard endoscopy was 55%.64 The results of other studies in 
similar high-risk populations also approved the validity of endos-
copy with iodine staining as an effective ESCC screening method 
in patients with head and neck cancers.65–69
Yokoyama, et al.70 conducted a screening program for early de-
tection of EC on a cohort of 629 high- risk individuals in Japan 
(alcoholic males) and concluded that chromoendoscopy is a useful 
method to detect dysplastic and neoplastic lesions of the esopha-
gus. Ban, et al. similarly showed the usefulness of endoscopy with 
iodine staining to detect early stages of EC in alcoholics.71 In a 
study from Brazil, Lugol chromoendoscopy was used to detect 
ESD in 190 high-risk asymptomatic males (those who consumed 
alcohol, cigarette, and mate) and ESDs were successfully detect-
ed.72 In a study on 225 healthy adults from a high EC-risk area in 
China, Dawsey, et al. found an increase, from 62% (before iodine 
staining) to 96% (after staining), in sensitivity of endoscopic ex-
amination for identifying high- grade ESD or ESCC.41 The results 
showed that 55% of moderate ESD and 23% of severe ESD were 
detected only after staining.
Chromoendoscopy was also reported to be useful in assessing 
the characteristics of esophageal mucosal lesions. It was reported 
to be effective in identifying margin lines of the lesions.73 Mori, et 
al. found that the thickness of the glycogen-containing cell layer 
ZDVZHOOLGHQWL¿HGE\VWDLQLQJLQWHQVLW\7KHLUUHVXOWVVKRZHGWKDW
Lugol test can be used for precise delineation of borders of the 
lesions.50 Kuwano, et al. similarly suggested endoscopic examina-
tion with Lugol staining as useful method to identify borders of 
early stages of EC.74 Dawsey, et al. also found a positive relation-
ship between size of unstained lesions and histologic diagnosis of 
the lesions (high-grade ESD or ESCC). They reported that the bor-




method for diagnosis of abnormal esophageal mucosal lesions in 
different research projects.42,75 However, because of some limita-
tions, it may not be accepted at population level in some high-risk 
UHJLRQVLQFOXGLQJQRUWKHDVWHUQ,UDQ7KH¿UVWOLPLWDWLRQLVWKDWHQ-
doscopy is an invasive procedure. Its costs may be relatively high, 
especially in low-resources communities. In addition, the Lugol’s 
solution may cause complications including retrosternal pain and 
discomfort and even erosions or ulcers in the esophagus (due to 
mucosal irritation).76 
There is also another important limitation for this technique. The 
UHVXOWVRIVRPHVWXGLHVVXJJHVWHGWKDWWKHVSHFL¿FLW\RIFKURPRHQ-
doscopy for detecting ESD and early stages of ESCC was low. So, 
VRPHLQYHVWLJDWRUVWULHGWR¿QGDSSOLFDEOHPHWKRGVWRLPSURYHLWV
VSHFL¿FLW\,VKLKDUDHWDOFRQVLGHUHGWKHSDWWHUQRIFRORUFKDQJH
after iodine staining for this reason.77 After using Logol’s solu-
tion during endoscopic examination, the neoplastic lesions of the 
esophagus initially change into whitish yellow color and then pink 
two to three minutes later. This pattern is called as pink sign in 
chromoendoscopy. Using this sign, Ishihara, et al. reported an ac-
FHSWDEOHDFFXUDF\VHQVLWLYLW\ DQGVSHFL¿FLW\ IRU
chromoendoscopy to detect early stages of esophageal neoplasias. 
Further studies are warranted to determine if this technique is ap-
plicable for other high-risk areas. Anyway, modifying the standard 
chromoendoscopy may be helpful to develop a more applicable 
screening program for ESCC. Overall, considering chromoen-
doscopy for developing ESCC screening program should be in-
dividualized for each community. When cost-effectiveness and 
adherence of people, despite invasiveness of the procedure, are 
acceptable, chromoendoscopy may be used for population- level 
screening. Otherwise, nonendoscopic screening programs may be 
considered.44
Endoscopic tissue imaging without staining
+HUHZHEULHÀ\UHYLHZVRPHUHFHQWO\GHYHORSHGHQGRVFRSLFLP-
aging modalities that do not use staining. However, the validity 
of almost all of these methods in detecting ESD and early-stage 
ESCC is under question and needs further investigation. These 
methods are generally expensive and are not available in many 
populations, in particular low-resources countries in which most 
of high ESCC-risk areas are located.1 Therefore, these methods do 




Archives of Iranian Medicine, Volume 16, Number 6, June 2013354
(QGRVFRSLF6FUHHQLQJIRU(6&&
quential illumination system is used to enhance the accuracy of 
diagnosis.78 As a result, contrast between the epithelial surface and 
the vascular pattern is increased and different images will be pro-
duced at various levels of the mucosa, resulting in similar contrast 
enhancement when compared to Lugol chromoendoscopy.79 Add-
ing NBI to standard endoscopy was helpful in early detection of 
ESCC.80  Improvement in visualization of the intrapapillary capil-
lary loops was the main advantage of this technique.80 Different 
LQYHVWLJDWRUVUHSRUWHGKLJKVHQVLWLYLW\DQGVSHFL¿FLW\IRU1%,WR
detect neoplastic lesions in esophageal mucosa.81–83 Muto, et al. 
UHSRUWHGDVHQVLWLYLW\RIDQGDVSHFL¿FLW\RIIRU1%,
V\VWHP WRGHWHFW VHFRQGDU\ VXSHU¿FLDO(6&& OHVLRQV LQSDWLHQWV
with head and neck cancer. They suggested NBI as the standard 




sessed by Ishihara, et al. They found that brownish epithelium and 
EURZQLVKGRWVDUHWKHPRVWLPSRUWDQW1%,¿QGLQJVWREHXVHGIRU
diagnosis of high-grade squamous neoplasia of the esophagus.85 
7KLV¿QGLQJQHHGVWREHLQYHVWLJDWHGLQODUJHUPXOWLFHQWHUVWXGLHV
to determine if it is applicable at population levels. There is another 
limitation for using NBI in primary care setting. Experience of en-
doscopist is an important issue for achieving successful results in 
NBI method. The results of a study from Japan showed that the 
sensitivity of NBI for detecting high-grade squamous neoplasia of 
WKHHVRSKDJXVZDVVLJQL¿FDQWO\KLJKHULQH[SHULHQFHGHQGRVFRSLVW
(100%) than less experienced endoscopist (69%).86
7KHEHQH¿WRIDFRPELQDWLRQRI1%,V\VWHPDQGPDJQLI\LQJHQ-
doscopy has been assessed in some studies. Yoshida, et al. reported 
more accurate assessment of esophageal lesions by considering 
such combination.87 Goda, et al.88 and Kawahara, et al.89 also sug-
gested that magnifying NBI endoscopy may be helpful for detect-
LQJDQGGLDJQRVLQJVXSHU¿FLDO(6&&
Confocal microscopy
 In this method, the standard endoscope is combined with mi-
FURVFRSHLPDJHSURFHVVLQJXQLW$GGLQJÀXRUHVFHQWDJHQWVDFUL-
ÀDYLQHK\GURFKORULGHRUÀXRUHVFHLQVRGLXPZLOOSURYLGHFHOOXODU
and histologic details of the tissue, resulting in detection of muco-
sal lesions.90 Liu, et al. used confocal laser endomicroscopy (CLE) 
WRGHWHFWVXSHU¿FLDO(6&&7KH\IRXQGWKDW&/(FDQVXFFHVVIXOO\
distinguish cancerous from normal epithelium and suggested it as 
a potential good method for early detection of EC.91 The poten-
WLDOSUREOHPZLWK WKLVV\VWHPLV WKHGLI¿FXOW\ LQREWDLQLQJJRRG
images. Further studies are needed to improve the validity of this 
method to detect mucosal lesions.
Endocytoscopy
 This method makes it possible to observe the cellular nuclei in 
the GI tract in vivo. Endocytoscoy system has been used to assess 
the characteristics of cells on the surface layer of early stages of 
ECs.92 By using this method it was possible to observe detailed 
histologic changes in esophageal lesions.93 Fujishiro, et al. report-
HGVLJQL¿FDQWGLIIHUHQFHLQFKDUDFWHULVWLFVRIHVRSKDJHDOHSLWKHOLDO
cells between cancerous and normal areas.94 They found close cor-
UHODWLRQEHWZHHQHQGRF\WRVFRSLFLPDJHVDQGKLVWRORJLF¿QGLQJRI
the esophageal biopsies. Evidences of neoplastic changes includ-
ing, increased cell density and nuclear abnormalities were reported 
in 84% of biopsy samples from ESCC cases.95
 Fluorescence endoscopy
,QWKLVPHWKRGUHDOWLPHÀXRUHVFHQFHLPDJHVDUHSURYLGHGE\
DGGLQJ ÀXRUHVFHQFH DJHQW WR VWDQGDUG HQGRVFRSH XVLQJ LPDJH
processing module.903ROJODVHHWDOVXFFHVVIXOO\XVHGDÀXRUHV-
cence confocal endomicroscope to assess GI tract. They showed 
that this new method may be considered to visualize the cellular 
and subcellular structures of squamous epithelium of the esopha-
gus and may be helpful to assess abnormal epithelial lesions of the 
esophagus.96 Uedo, et al. used a videoendoscopy system with auto-
ÀXRUHVFHQFHDQGUHÀHFWDQFHIRUHDUO\GHWHFWLRQRI(&V7KH\FRXOG
¿QGRIVXSHU¿FLDO(&VXVLQJWKLVPHWKRGDQGUHSRUWHGWKDW
their method had an advantage over standard videoendoscopy.97 
However, the accuracy of this method in another study, was less 
than chromoendoscopy and NBI.98
Trimodal imaging
 This technique consists of a combination of white-light endos-
FRS\DXWRÀXRUHVFHQFHDQG1%,6RPHVWXGLHVUHSRUWHGWKDWWKLV
method may improve the detection of Barrett’s dysplasia compared 
with standard endoscopy.99–101 It may be considered for early detec-
tion of ESCC premalignant and malignant lesion. Future studies 
are needed to assess validity of this technique to detect ESDs and 
early stages of ESCC.
Optical coherence tomography
In this method, low-coherence infrared light is used to produce a 
high-resolution image of the epithelium.90 It was used to diagnosis 
Barrett’s dysplasia in the esophagus.102 But its sensitivity was too 
low to be used in clinical setting.103 Further studies are warranted 
to assess the validity of this method to detect esophageal squamous 
lesions.
Elastic scattering spectroscopy
 This procedure is based on measurement of the epithelial elastic 
scattering index. This index may change as a result of alterations 
in cellular components (including nucleus and mitochondria) dur-
ing neoplastic process. It is measured by inserting an optical probe 
through the instrument channel of the endoscope. A high sensitivi-
ty was reported for this technique to detect dysplasia and neoplasia 
in Barrett’s esophagus.104 Future studies are needed to determine if 
this method is also helpful for early detection of ESCC.
Conclusion
Designing endoscopic ESCC screening program should be in-
dividualized for each population. Similar to all population-based 
screening programs, any screening for early detection of ESCC 
must be cost-effective; otherwise, screening may not be indicated 
in that population. Endoscopy with iodine staining has been ac-
cepted as a population-level ESCC screening program in some 
high-risk areas including parts of China. This method may be too 
expensive and invasive in other high-risk communities. Nonen-
doscopic methods may be more applicable in these populations 
for population-based screenings. The limitations (questionable 
validity and costs) of new endoscopic imaging modalities, includ-
ing NBI, made them inappropriate to be used in population-level 
ESCC screening programs. Low-cost, less-invasive endoscopic 
imaging methods with acceptable diagnostic performance may 
make screening of ESCC in high-risk areas cost-effective.
         
Archives of Iranian Medicine, Volume 16, Number 6, June 2013 355
*5RVKDQGHO$1RURX]L$3RXUVKDPVHWDO
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Globo-
can 2008, cancer incidence and mortality worldwide: Iarc cancerbase no. 
10.  Lyon: International Agency for Research on Cancer; 2010. Available 
from: URL: http://globocan.iarc.fr (Accessed Date: 03/02/2011) 
2. Bird-Lieberman EL, Fitzgerald RC. Early diagnosis of oesophageal can-
cer. Br J Cancer. 2009; 101: 1 – 6.
3. Das A. Tumors of the esophagus. In: Feldman M, Friedman L, Brandt 
LJ, editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: 
Pathophysiology, Diagnosis, and Management. 9th ed. Philadelphia: 
Saunders Elsevier; 2010. 745 – 770.
4. Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S. 
Oesophageal cancer studies in the Caspian Littoral of Iran: The Caspian 
Cancer Registry. Br J Cancer. 1973; 28: 197 – 214.
5. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer 
Incidence in Five Continents, vol. Viii. Lyon: IARC; 2002.
6. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demograph-
ic variations in the rising incidence of esophageal adenocarcinoma in 
white males. Cancer. 2001; 92: 549 – 555.
7. Brown LM, Devesa SS, Chow W-H. Incidence of adenocarcinoma of the 
esophagus among white Americans by sex, stage, and age. J Natl Cancer 
Inst. 2008; 100: 1184 – 1187.
8. Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal 
adenocarcinoma. J Surg Oncol. 2005; 92: 151 – 159.
9. Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in 
northeastern Iran: a review. Arch Iran Med. 2007; 10: 70 – 82.
10. Islami F, Kamangar F, Nasrollahzadeh D, Moller H, Boffeta P, Malekza-
deh R. Oesophageal cancer in Golestan Province, a high-incidence area 
in northern Iran - a review. Eur J Cancer. 2009;  3156 – 3165.
11. Roshandel G, Sadjadi A, Aarabi M, Keshtkar A, Sedaghat S, Nouraie 
S, et al. Cancer incidence in Golestan Province: report of an ongoing 
population-based cancer registry in Iran between 2004 and 2008. Arch 
Iran Med. 2012; 15: 196.
12. Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, et al. 
Squamous esophageal histology and subsequent risk of squamous cell 
carcinoma of the esophagus. A prospective follow-up study from Linx-
ian, China. Cancer. 1994;  1686 – 1692.
13. Wang GQ, Abnet CC, Shen Q, Lewin KJ, Sun XD, Roth MJ, et al. His-
tological precursors of oesophageal squamous cell carcinoma: Results 
from a 13-year prospective follow-up study in a high-risk population. 
Gut. 2005;  187 – 192.
14. Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins and Cotran 
Pathologic Basis of Disease. 8th ed. Philadelphia: Saunders Elsevi-
er.2010 . 842 – 851
15. Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes 
of esophageal cancer. Gastroenterol Clin North Am. 2009; 38: 27 – 57.
16. Akbari M, Malekzadeh R, Lepage P, Roquis D, Sadjadi A, Aghcheli K, 
et al. Mutations in Fanconi anemia genes and the risk of esophageal can-
cer. Hum Genet. 2011; 129: 573 – 582.
17. Akbari MR, Malekzadeh R, Nasrollahzadeh D, Amanian D, Islami F, Li 
S, et al. Germline brca2 mutations and the risk of esophageal squamous 
cell carcinoma. Oncogene. 2007;  1290 – 1296.
18. Abedi-Ardekani B, Kamangar F, Hewitt SM, Hainaut P, Sotoudeh M, 
Abnet CC, et al. Polycyclic aromatic hydrocarbon exposure in oesopha-
geal tissue and risk of oesophageal squamous cell carcinoma in north-
eastern Iran. Gut. 2010; 59: 1178 – 1183.
19. Semnani S, Roshandel G, Zendehbad A, Keshtkar A, Rahimzadeh H, 
Abdolahi N, et al. Soils selenium level and esophageal cancer: An eco-
logical study in a high-risk area for esophageal cancer. J Trace Elem Med 
Biol. 2010;  174 – 177.
20. Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollen-
beck AR, et al. A prospective study of tobacco, alcohol, and the risk of 
esophageal and gastric cancer subtypes. Am J Epidemiol. 2007; 165: 
1424.
21. Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, Ab-
net CC, et al. Opium, tobacco, and alcohol use in relation to oesophageal 
squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008; 
98: 1857 – 1863.
22. Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shak-
eri R, et al. Tea drinking habits and oesophageal cancer in a high risk 
area in northern Iran: population based case-control study. BMJ. 2009; 
338: b929.
23. Castellsague X, Munoz N, De Stefani E, Victora CG, Castelletto R, Ro-
ORQ3$,QÀXHQFHRIPDWHGULQNLQJKRW beverages, and diet on esopha-
geal cancer risk in South America. Int J Cancer. 2000; 88: 658 – 664.
24. Freedman ND, Park Y, Subar AF, Hollenbeck AR, Leitzmann MF, 
Schatzkin A, et al. Fruit and vegetable intake and esophageal cancer in 
a large prospective cohort study. Int J Cancer. 2007; 121: 2753 – 2760.
25. Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, 
Abedi-Ardekani B, et al. Socio-economic status and oesophageal cancer: 
results from a population-based case-control study in a high-risk area. Int 
J Epidemiol. 2009; 38: 978 – 988.
26. Abnet CC, Kamangar F, Islami F, Nasrollahzadeh D, Brennan P, Agh-
cheli K, et al. Tooth loss and lack of regular oral hygiene are associated 
with higher risk of esophageal squamous cell carcinoma. Cancer Epide-
miol Biomarkers Prev. 2008;  3062 – 3068.
27. Ludeman L, Shepherd NA. Serosal involvement in gastrointestinal can-
FHU ,WVDVVHVVPHQWDQGVLJQL¿FDQFHHistopathology. 2005; : 123 – 
131.
28. (QGR0.DZDQR7'HWHFWLRQDQGFODVVL¿FDWLRQof early squamous cell 
esophageal cancer. Dis Esophagus. 1997; 10: 155 – 158.
29. Wang GQ. A 30-year experience on early detection and treatment of 
esophageal cancer in high- risk areas. Zhongguo Yi Xue Ke Xue Yuan Xue 
Bao. 2001; 23: 69 – 72.
30. Morimoto M, Nishiyama K, Nakamura S, Suzuki O, Kawaguchi Y, Na-
NDMLPD$HW DO6LJQL¿FDQFHRIHQGRVFRSLFscreening and endoscopic 
resection for esophageal cancer in patients with hypopharyngeal cancer. 
Jpn J Clin Oncol. 2010;  938 – 943.
31. Hiripi E, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et 
al. Survival of stomach and esophagus cancer patients in Germany in the 
early 21st century. Acta Oncologica. 2012; 51: 906 – 914.
32. Dubecz A, Gall I, Solymosi N, Schweigert M, Peters JH, Feith M, et 
al. Temporal trends in long-term survival and cure rates in esophageal 
cancer: a seer database analysis. J Thorac Oncol. 2012;  443 – 447.
33. Alidina A, Gaffar A, Hussain F, Islam M, Vaziri I, Burney I, et al. Surviv-
al data and prognostic factors seen in Pakistani patients with esophageal 
cancer. Ann Oncol. 2004; 15: 118 – 122.
34. Aghcheli K, Marjani HA, Nasrollahzadeh D, Islami F, Shakeri R, Sotou-
deh M, et al. Prognostic factors for esophageal squamous cell carcinoma-
-a population-based study in Golestan Province, Iran, a high- incidence 
area. PLoS ONE. 2011; 6: e22152.
35. Dong Z, Tang P, Li L, Wang G. The strategy for esophageal cancer con-
trol in high-risk areas of China. Jpn J Clin Oncol. 2002; 32: S10 – S12.
36. Liu ZR, Wei WQ, Huang YQ, Qiao YL, Wu M, Dong ZW. Economic 
evaluation of “early detection and treatment of esophageal cancer. Ai 
Zheng. 2006; 25: 200 – 203.
37. Yang J, Wei WQ, Niu J, Liu ZC, Yang &;4LDR</&RVWEHQH¿WDQDO\-
sis of esophageal cancer endoscopic screening in high-risk areas of Chi-
na. World J Gastroenterol. 2012; 18: 2493 – 2501.
38. Ancona E, Rampado S, Cassaro M, Battaglia G, Ruol A, Castoro C, et 
al. Prediction ofO\PSKQRGHVWDWXVLQVXSHU¿FLDOHVRSKDJHDOFDUFLQRPD
Ann Surg Oncol. 2008; 15: 3278 – 3288.
39. Makuuchi H, Nomura T, Mizutani K, Shimada H, Sugeno K, Chino O, 
et al. Endoscopic mucosal resection for early esophageal cancer by the 
eemr-tube method. I to Cho. 1993; 28: 153 – 159.
40. Gordis L, editor. Epidemiology. 4th ed. Philadelphia: Saunders Elsevier; 
2009.
41. Dawsey SM, Fleischer DE, Wang GQ, Zhou B, Kidwell JA, Lu N, et al. 
Mucosal iodine staining improves endoscopic visualization of squamous 
dysplasia and squamous cell carcinoma of the esophagus in Linxian, 
China. Cancer. 1998; 83: 220 – 231.
42. Roth MJ, Liu SF, Dawsey SM, Zhou B, Copeland C, Wang G-Q, et al. 
Cytologic detection of esophageal squamous cell carcinoma and precur-
sor lesions using balloon and sponge samplers in asymptomatic adults in 
Linxian, China. Cancer. 1997; 80: 2047 – 2059.
43. Chung CS, Lee YC, Wang CP, Ko JY, Wang WL, Wu MS, et al. Second-
ary prevention of esophageal squamous cell carcinoma in areas where 
smoking, alcohol, and betel quid chewing are prevalent. J Formos Med 
Assoc. 2010; 109: 408 – 421.
44. Roshandel G, Semnani S, Malekzadeh R. Non-endoscopic screening for 
esophageal squamous cell carcinoma-a review. MEJDD. 2012;  111 
– 124.
45. Schiller W. Early diagnosis of carcinoma of the cervix. Surg Gynecol 
Obstet. 1933; 59: 210 – 222.
46. Voegeli R. Die schillersche jodprobe im rahmen der ösophagusdiagnos-
tik. ORL. 1966; 28: 230 – 239.
47. Nothmann BJ, Wright JR, Schuster MM. In vivo vital staining as an aid 
WR LGHQWL¿FDWLRQRIHVRSKDJRJDVWULFPXFRVDO MXQFWLRQ in man. Dig Dis 
Sci. 1972;  919 – 924.
48. Toriie S, Kohli Y, Akasaka Y, Kawai K. New trial for endoscopical ob-
Archives of Iranian Medicine, Volume 16, Number 6, June 2013356
(QGRVFRSLF6FUHHQLQJIRU(6&&
servation of esophagus by dye scattering method ein neuer anlauf zur 
anfärbung der ösophagusmukosa während der endoskopie. Endoscopy. 
1975;  75 – 79.
49. Brodmerkel G. Schiller’s test: an aid in esophagoscopic diagnosis. Gas-
troenterology. 1971; 6: 813.
50. Mori M, Adachi Y, Matsushima T, Matsuda H, Kuwano H, Sugimachi K. 
Lugol staining pattern and histology of esophageal lesions. Am J Gastro-
enterol. 1993; 88: 701 – 705.
51. Miyazaki S, Kawahara K, Watanabe S, Hirata M, Iida Y, Okita K, et al. 
Fundamental studies on Lugol staining method of esophageal carcino-
mas. Gastroenterol Endosc. 1981; 23: 503 – 513.
52. Endo M, Ide H. Endoscopic staining in early diagnosis of esophageal 
FDQFHU-DSDQ6FLHQWL¿FSocieties Press; 1991.
53. Nakanishi Y, Ochiai A, Shimoda T, Yamaguchi H, Tachimori Y, Kato 
H, et al. Epidermization in the esophageal mucosa: Unusual epithelial 
changes clearly detected by Lugol’s staining. Am J Surg Pathol. 1997; 
21: 605 – 609.
54. Mandard AM, Tourneux J, Gignoux M, Blanc L, Segol P, Mandard JC. 
In situ carcinoma of the esophagus. Macroscopic study with particular 
reference to the Lugol test. Endoscopy. 1980; 12: 51 – 57.
55. Chen LQ, Hu CY, Ghadirian P, Duranceau A. Early detection of esopha-
geal squamous cell carcinoma and its effects on therapy: an overview. 
Dis Esophagus. 1999; 12: 161 – 167.
56. Chisholm EM, Williams SR, Leung JW, Chung SC, van Hasselt CA, Li 
AK. Lugol’s iodine dye-enhanced endoscopy in patients with cancer of 
the oesophagus and head and neck. Eur J Surg Oncol. 1992; 18: 550 – 
552.
57. Ina H, Shibuya H, Ohashi I, Kitagawa M. The frequency of a concomi-
tant early esophageal cancer in male patients with oral and oropharyn-
geal cancer. Screening results using Lugol dye endoscopy. Cancer. 1994; 
 2038 – 2041.
58. Meyer V, Burtin P, Bour B, Blanchi A, Cales P, Oberti F, et al. Endo-
scopic detection of early esophageal cancer in a high-risk population: 
does Lugol staining improve videoendoscopy? Gastrointest Endosc. 
1997;  480 – 484.
59. Misumi A, Harada K, Murakami A, Arima K, Kondo H, Akagi M, et al. 
Role of Lugol dye endoscopy in the diagnosis of early esophageal cancer. 
Endoscopy. 1990; 22: 12 – 16.
60. Shimizu Y, Tukagoshi H, Fujita M, Hosokawa M, Kato M, Asaka M. 
Endoscopic screening for early esophageal cancer by iodine staining in 
patients with other current or prior primary cancers. Gastrointest Endosc. 
2001; 53: 1 – 5.
61. Shiozaki H, Tahara H, Kobayashi K, Yano H, Tamura S, Imamoto H, 
et al. Endoscopic screening of early esophageal cancer with the Lugol 
dye method in patients with head and neck cancers. Cancer. 1990; 66: 
2068 – 2071.
62. Sugimachi K, Kitamura K, Baba K, Ikebe M, Kuwano H. Endoscopic 
diagnosis of early carcinoma of the esophagus using Lugol’s solution. 
Gastrointest Endosc. 1992; 38: 657 – 661.
63. Freitag CP, Barros SG, Kruel CD, Putten AC, Dietz J, Gruber AC, et al. 
Esophageal dysplasias are detected by endoscopy with Lugol in patients 
at risk for squamous cell carcinoma in southern Brazil. Dis Esophagus. 
1999; 12: 191 – 195.
64. Hashimoto CL, Iriya K, Baba ER, Navarro-Rodriguez T, Zerbini MC, 
Eisig JN, et al. Lugol’s dye spray chromoendoscopy establishes early 
diagnosis of esophageal cancer in patients with primary head and neck 
cancer. Am J Gastroenterol. 2005; 100: 275 – 282.
65. Makuuchi H, Machimura T, Shimada H, Mizutani K, Chino O, Kise Y, et 
al. Endoscopic screening for esophageal cancer in 788 patients with head 
and neck cancers. Tokai J Exp Clin Med. 1996; 21: 139 – 145.
66. Dubuc J, Legoux JL, Winnock M, Seyrig JA, Barbier JP, Barrioz T, et al. 
Endoscopic screening for esophageal squamous-cell carcinoma in high-
risk patients: a prospective study conducted in 62 French endoscopy cen-
ters. Endoscopy. 2006; 38: 690 – 695.
67. Moschler O, Spahn TW, Middelberg-Bisping C, Grosse-Thie W, Chris-
toph B, Kloeppel G, et al. Chromoendoscopy is a valuable tool for 
screening of high-risk patients with head and neck cancer for early detec-
tion of esophageal cancer. Digestion. 2006;  160 – 166.
68. Tincani AJ, Brandalise N, Altemani A, Scanavini RC, Valerio JB, Lage 
HT, et al. 'LDJQRVLVRIVXSHU¿FLDOHVRSKDJHDOFDQFHUDQGG\VSODVLDXVLQJ
endoscopic screening with a 2% Lugol dye solution in patients with head 
and neck cancer. Head Neck. 2000; 22: 170 – 174.
69. Scherubl H, Lampe BV, Faiss S, Daubler P, Bohlmann P, Plath T, et al. 
Screening for oesophageal neoplasia in patients with head and neck can-
cer. Br J Cancer. 2002; 86: 239 – 243.
70. Yokoyama A, Ohmori T, Makuuchi H, Maruyama K, Okuyama K, Taka-
hashi H, et al. Successful screening for early esophageal cancer in alco-
holics using endoscopy and mucosa iodine staining. Cancer. 1995;  
928 – 934.
71. Ban S, Toyonaga A, Harada H, Ikejiri N, Tanikawa K. Iodine staining for 
early endoscopic detection of esophageal cancer in alcoholics. Endos-
copy. 1998; 30: 253 – 257.
72. Fagundes R, De Barros S, Pütten A, Mello E, Wagner M, Bassi L, et al. 
Occult dysplasia is disclosed by Lugol chromoendoscopy in alcoholics 
at high risk for squamous cell carcinoma of the esophagus. Endoscopy. 
1999; 31: 281 – 285.
73. Nabeya K, Hanaoka T, Onozawa K, Ri S, Nyumura T, Kaku C. Early 
diagnosis of esophageal cancer. Hepatogastroenterology. 1990;  368 
– 370.
74. Kuwano H, Kitamura K, Baba K, Morita M, Matsuda H, Mori M, et al. 
Determination of the resection line in early esophageal cancer using in-
traoperative endoscopic examination with Lugol staining. J Surg Oncol. 
1992; 50: 149 – 152.
75. Pan QJ, Roth MJ, Guo HQ, Kochman ML, Wang GQ, Henry M, et 
al. Cytologic detection of esophageal squamous cell carcinoma and its 
precursor lesions using balloon samplers and liquid-based cytology in 
asymptomatic adults in Linxian, China. Acta Oncologica. 2008; 52: 14 
– 23.
76. Kondo H, Fukuda H, Ono H. Sodium thiosulfate solution spray for relief 
of irritation caused by Lugol’s stain in chromoendoscopy. Gastrointest 
Endosc. 2001; 53: 199 – 202.
77. Ishihara R, Yamada T, Iishi H, Kato M, Yamamoto S, Yamamoto S, et 
al. Quantitative analysis of the color change after iodine staining for di-
agnosing esophageal high-grade intraepithelial neoplasia and invasive 
cancer. Gastrointest Endosc. 2009; 69: 213 – 218.
78. Tajiri H, Matsuda K, Fujisaki J. What can we see with the endoscope? 
Present status and future perspectives. Digestive Endoscopy. 2002;  
131 – 137.
79. Kara MA, Peters FP, Rosmolen WD, Krishnadath KK, Ten Kate FJ, 
Fockens P, et al. High-resolution endoscopy plus chromoendoscopy or 
narrow-band imaging in Barrett’s esophagus: A prospective randomized 
crossover study. Endoscopy. 2005;  929 – 936.
80. Gheorghe C. Narrow-band imaging endoscopy for diagnosis of malig-
nant and premalignant gastrointestinal lesions. J Gastrointestin Liver 
Dis. 2006; 15: 77.
81. Lee Y-C, Wang C-P, Chen C-C, Chiu H-M, Ko J-Y, Lou P-J, et al. Trans-
nasal endoscopy with narrow-band imaging and Lugol staining to screen 
patients with head and neck cancer whose condition limits oral intuba-
tion with standard endoscope (with video). Gastrointest Endosc. 2009; 
69: 408 – 417.
82. Takenaka R, Kawahara Y, Okada H, Hori K, Inoue M, Kawano S, et al. 
Narrow-band imaging provides reliable screening for esophageal malig-
nancy in patients with head and neck cancers. Am J Gastroenterol. 2009; 
 2942 – 2948.
83. Lecleire S, Antonietti M, Iwanicki-Caron I, Duclos A, Lemoine F, Pes-
sot FL, et al. Lugol chromoendoscopy versus narrow- band imaging for 
endoscopic screening of esophageal squamous-cell carcinoma in patients 
with a history of cured esophageal cancer: a feasibility study. Dis Esoph-
agus. 2011;  418 – 422.
84. Muto M, Minashi K, Yano T, Saito Y, Oda I, Nonaka S, et al. Early detec-
WLRQRIVXSHU¿FLDOVTXDPRXVFHOOFDUFLQRPDLQWKHhead and neck region 
and esophagus by narrow-band imaging: a multicenter randomized con-
trolled trial. J Clin Oncol. 2010; 28: 1566 – 1572.
85. Ishihara R, Inoue T, Uedo N, Yamamoto S, Kawada N, Tsujii Y, et al. 
6LJQL¿FDQFHRIHDFKQDUURZEDQGLPDJLQJ¿QGLQJLQGLDJQRVLQJVTXD-
mous mucosal high-grade neoplasia of the esophagus. J Gastroenterol 
Hepatol. 2010; 25: 1410 – 1415.
86. Ishihara R, Takeuchi Y, Chatani R, Kidu T, Inoue T, Hanaoka N, et al. 
Original article: Prospective evaluation of narrow-band imaging endos-
copy for screening of esophageal squamous mucosal high-grade neopla-
sia in experienced and less experienced endoscopists. Dis Esophagus. 
2010; 23: 480 – 486.
87. Yoshida T, Inoue H, Usui S, Satodate H, Fukami N, Kudo SE. Narrow-
band imagingV\VWHPZLWKPDJQLI\LQJHQGRVFRS\IRUVXSHU¿FLDOHVRSKD-
geal lesions. Gastrointest Endosc. 2004; 59: 288 – 295.
88. Goda K, Tajiri H, Ikegami M, Yoshida Y, Yoshimura N, Kato M, et al. 
Magnifying endoscopy with narrow-band imaging for predicting the 
invasion depth RIVXSHU¿FLDOHVRSKDJHDOVTXDPRXVFHOOFDUFLQRPDDis 
Esophagus. 2009; 22: 453 – 460.
89. Kawahara Y, Uedo N, Fujishiro M, Goda K, Hirasawa D, Lee JH, et al. 
The usefulness of NBIPDJQL¿FDWLRQRQGLDJQRVLVRIVXSHU¿FLDO esopha-
geal squamous cell carcinoma. Dig Endosc. 2011; 23: 79 – 82.
Archives of Iranian Medicine, Volume 16, Number 6, June 2013 357
*5RVKDQGHO$1RURX]L$3RXUVKDPVHWDO
90. Kwon RS, Sahani DV, Brugge WR. Gastrointestinal cancer imaging: 
Deeper than the eye can see. Gastroenterology. 2005; 128: 1538 – 1553.
91. Liu H, Li YQ, Yu T, Zhao YA, Zhang JP, Zuo XL, et al. Confocal laser 
HQGRPLFURVFRS\ IRU VXSHU¿FLDO HVRSKDJHDO VTXDPRXV FHOO FDUFLQRPD
Endoscopy. 2009;  99 – 106.
92. Tomizawa Y, Abdulla HM, Prasad GA, Wong Kee Song L-M, Lutzke 
LS, Borkenhagen LS, et al. Endocytoscopy in esophageal cancer. Gas-
trointest Endosc Clin N Am. 2009; 19: 273 – 281.
93. Kumagai Y, Monma K, Kawada K. Magnifying chromoendoscopy of 
the esophagus: in-vivo pathological diagnosis using an endocytoscopy 
system. Endoscopy. 2004; 36: 590 – 594.
94. Fujishiro M, Takubo K, Sato Y, Kaise M, Niwa Y, Kato M, et al. Potential 
and present limitation of endocytoscopy in the diagnosis of esophageal 
squamous-cell carcinoma: A multicenter ex vivo pilot study. Gastrointest 
Endosc. 2007; 66: 551 – 555.
95. Kumagai Y, Kawada K, Yamazaki S, Iida M, Ochiai T, Momma K, et 
al. Endocytoscopic observation of esophageal squamous cell carcinoma. 
Digestive Endoscopy. 2010; 22: 10 – 16.
96. Polglase AL, Mclaren WJ, Skinner SA, Kiesslich R, Neurath MF, Del-
aney PM. $ÀXRUHVFHQFHFRQIRFDOHQGRPLFURVFRSHIRUin vivo micros-
copy of the upper- and the lower-GI tract. Gastrointest Endosc. 2005; 
62: 686 – 695.
97. Uedo N, Iishi H, Tatsuta M, Yamada T, Ogiyama H, Imanaka K, et al. A 
novel videoendoscopy systemE\XVLQJDXWRÀXRUHVFHQFHDQGUHÀHFWDQFH
imaging for diagnosis of esophagogastric cancers. Gastrointest Endosc. 
2005; 62: 521 – 528.
98. Lopes AB, Fagundes RB. Esophageal squamous cell carcinoma - pre-
cursor lesions and early diagnosis. World J Gastrointest Endosc. 2012; 
 9 – 16.
99. Kara MA, Smits ME, Rosmolen WD, Bultje AC, Ten Kate FJ, Fockens 
P, et al. A randomized crossover study comparing lightLQGXFHGÀXR-
rescence endoscopy with standard videoendoscopy for the detection of 
early neoplasia in Barrett’s esophagus. Gastrointest Endosc. 2005; 61: 
671 – 678.
100. Wolfsen HC, Crook JE, Krishna M, Achem SR, Devault KR, Bouras EP, 
et al. Prospective, controlled tandem endoscopy study of narrow-band 
imaging for dysplasia detection in Barrett’s esophagus. Gastroenterol-
ogy. 2008; 135: 24 – 31.
101. Curvers W, Fockens P, Bergman J, Singh R, Ragunath K, Wong Kee 
Song L, et al. Endoscopic trimodal imaging improves the detection of 
high-grade dysplasia (HGD) and early cancer (EC) in Barrett’s esopha-
gus: an international multicenter study. Gastroenterology. 2007; 132: 
2586 – 2586.
102. Poneros JM, Nishioka NS. Diagnosis of Barrett’s esophagus using opti-
cal coherence tomography. Gastrointest Endosc Clin N Am. 2003; 13: 
309.
103. Testoni PA, Mangiavillano B. Optical coherence tomography in detec-
tion of dysplasia and cancer of the gastrointestinal tract and bilio-pancre-
atic ductal system. World J Gastroenterol. 2008;  6444 – 6452.
104. Lovat LB, Johnson K, Mackenzie GD, Clark BR, Novelli MR, Davies S, 
et al. Elastic scattering spectroscopy accurately detects high-grade dys-
plasia and cancer in Barrett’s oesophagus. Gut. 2006; 55: 1078 – 1083.
Eram Garden (Baghe Eram), Shiraz, Fars Province, Iran (photo M.H.Azizi MD)
